Haryana Health Minister Anil Vij Volunteers for Covaxin Phase 3 Trials; Bharat Biotech's COVID-19 Vaccine To Begin Trials in State from November 20

·2-min read

New Delhi, November 18: Haryana Health Minister Anil Vij, on Wednesday, said that he volunteered for getting the first Covaxin shot as the COVID-19 vaccine enters its third phase of human trials. The phase three trials in Haryana are set to begin from November 20. Vij took to Twitter and wrote, "Trial for third phase of Covaxin a coronavirus vaccine product of Bharat Biotech to start in Haryana on 20th November. I have offered myself as first volunteer to get vaccinated." Covaxin: Bharat Biotech's COVID-19 Vaccine into Phase-3 Trials.

Also Read | Hari Chand Hooda, 100-Year-Old Former MLA Who Once Defeated Bhupinder Singh Hooda, Now Beats Coronavirus

In phase three trials, the vaccine will be tested on people above 18 years of age.About 25,800 volunteers will be given measured doses of Covaxin in the third phase at 25 centres across the country. The phase three trials of the Bharat Biotech's COVID-19 vaccine have already begun in Hyderabad on November 16. COVID-19 Vaccine Update: Bharat Biotech's COVAXIN Vaccine Could be Launched as Early as February 2021, Says ICMR Senior Scientist.

Read the Tweet by Anil Vij Here:

Also Read | 'We Believe Lockdown is Not a solution in Fight Against COVID-19,' Says Delhi Deputy CM Manish Sisodia: Live Breaking News Headlines Updates on November 18, 2020

This content is not available due to your privacy preferences.
Update your settings here to see it.

The first and second phase trials of Covaxin, India's first indigenous COVID-19 vaccine, have largely been successful. In Phase one, two doses of Covaxin were administered to healthy volunteers in the age-group of 18 to 55 years, while in Phase two, as many doses were given to a different set of volunteers in the age-group of 12 to 65 years.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting